Patent: 10,092,513
✉ Email this page to a colleague
Summary for Patent: 10,092,513
Title: | Treatment of diabetes mellitus by long-acting formulations of insulins |
Abstract: | The application relates to an aqueous pharmaceutical formulation for use in the treatment of Type I or Type II Diabetes Mellitus, wherein the treatment reduces the risk of nocturnal hypoglycemia, said formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine, with the proviso that the concentration of said formulation is not 684 U/mL of insulin glargine. |
Inventor(s): | Muhlen-Bartmer; Isabel (Frankfurt am Main, DE), Ziemen; Monika (Frankfurt am Main, DE) |
Assignee: | SANOFI (Paris, FR) |
Application Number: | 14/781,857 |
Patent Claims: | see list of patent claims |
Details for Patent 10,092,513
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Sanofi-aventis U.s. Llc | LANTUS | insulin glargine | Injection | 021081 | 04/20/2000 | ⤷ Try a Trial | 2033-04-03 |
Sanofi-aventis U.s. Llc | LANTUS | insulin glargine | Injection | 021081 | 04/25/2007 | ⤷ Try a Trial | 2033-04-03 |
Eli Lilly And Company | BASAGLAR | insulin glargine | Injection | 205692 | 12/16/2015 | ⤷ Try a Trial | 2033-04-03 |
Eli Lilly And Company | BASAGLAR | insulin glargine | Injection | 205692 | 11/15/2019 | ⤷ Try a Trial | 2033-04-03 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |